9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2021-04-12T11:17:54+02:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|0 Comments

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

13 01, 2020

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

2020-01-13T09:00:05+01:00January 13th, 2020|biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|0 Comments

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to read the story